"In vivo" and "in vitro" inhibition of human pancreatic chymotrypsin A by serum inhibitors.
The interaction of human pancreatic chymotrypsin A with serum inhibitors was assessed by enzyme immunoassay, enzymatic activity and inhibitory capacity measurements and electrophoretic analyses. In normal serum, chymotrypsin A was detected in four forms: one form (Mr approximately equal to 25,000) which might be chymotrypsinogen A and three forms complexed to the main inhibitors present in serum, alpha 2-macroglobulin (alpha 2-M), alpha 1-proteinase inhibitor (alpha 1-PI) and alpha 1-antichymotrypsin (alpha 1-Achy). As chymotrypsin A remains to 90% active when bound to alpha 2-M, the chymotrypsin A/alpha 2-M complex was quantified by an enzymatic assay. The kinetic parameters of the interaction of chymotrypsin A with alpha 1-PI and alpha 1-Achy were determined. Using these data the partition of chymotrypsin A between the different inhibitors in serum was calculated. In acute pancreatitis, the chymotrypsin A plasma level follows the progression of the disease and in this case as well as in normal serum alpha 1-PI is the major antagonist of chymotrypsin A.
D001798:Blood Proteins / Q000378:metabolism; D002918:Chymotrypsin / Q000037:antagonists & inhibitors* / Q000097:blood; D004791:Enzyme Inhibitors / Q000097:blood*; D006801:Humans; D066298:In Vitro Techniques; D010179:Pancreas / Q000201:enzymology*; D010195:Pancreatitis / Q000097:blood / Q000201:enzymology; D000514:alpha 1-Antichymotrypsin / Q000097:blood; D000515:alpha 1-Antitrypsin; D000511:alpha-Macroglobulins / Q000378:metabolism
D001798:Blood Proteins; D004791:Enzyme Inhibitors; D000514:alpha 1-Antichymotrypsin; D000515:alpha 1-Antitrypsin; D000511:alpha-Macroglobulins; D002918:Chymotrypsin